Skip to main content

Is Tresiba the same as Lantus?

Medically reviewed by Carmen Pope, BPharm. Last updated on June 19, 2024.

Official Answer by Drugs.com

Tresiba (insulin degludec)

Tresiba is an ultra-long-acting human insulin analog (insulin degludec) that is given by subcutaneous injection (under the skin) for the treatment of diabetes in adults and children over the age of one year.

Tresiba costs approximately $363.36 for 10ml vial of 100 units/mL.

There are two types of Tresiba FlexTouch pen:

Tresiba is also available in a 10mL vial. The vial contains 1000 units of Tresiba.

Lantus (insulin glargine)

Lantus is a long-acting human insulin analog (insulin glargine) that is given by subcutaneous injection (under the skin) for the treatment of diabetes in adults and children over the age of six years.

Lantus is available as

Lantus is also available in a 10mL vial. The vial contains 1000 units of Lantus.

A 10ml vial of Lantus U-100 costs approximately $305.53.

Related questions

How is Tresiba made?

Tresiba (insulin degludec) is made using genetic engineering technology. Although it resembles human insulin in most of its structure, the amino acid threonine in position B30 has been replaced by a side chain containing glutamine and a C16 fatty acid. Tresiba exists as stable insulin dihexamers bonded by zinc.

Once Tresiba is injected, the insulin dihexamers form multihexamers. The rate of insulin absorption depends on the size of the insulin molecules, so these large insulin hexamers stay in place, creating an insulin depot (storage). With time the zinc diffuses, which releases insulin monomers from each end of the chain. These monomers are the correct size for absorption into the bloodstream.

Because of the slow and steady way Tresiba breaks up and diffuses under the skin, it lasts for at least 42 hours. This means Tresiba can be dosed once a day, at any time of the day.

How is Lantus made?

Lantus (insulin glargine) is made using genetic engineering technology. Although it resembles human insulin in most of its structure, the amino acid arginine in position A21 has been replaced by glycine and two arginines have been added to the C-terminus of the B-chain.

Lantus was formulated to have a low insulin solubility at neutral pH which means it forms microprecipitates once injected subcutaneously from which insulin glargine is slowly released.

It is released relatively slowly over 24 hours with no pronounced peak. The primary activity of insulin, including Lantus, is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy.

References

Read next

Soliqua vs Lantus: What’s the difference between them?

Soliqua is a combination of insulin glargine plus lixisenatide, and Lantus only contains insulin glargine. Both are once-daily injections that are given under the skin (subcutaneously), but Soliqua can only be used in adults with type 2 diabetes whereas Lantus may be used to treat both type 1 and type 2 diabetes in adults and children over the age of six years. Both are made by Sanofi-Aventis. Continue reading

Is Admelog the same as NovoLog?

No, Admelog (insulin lispro) is not the same as NovoLog (insulin aspart). These insulins have different chemical structures but they are both man-made, rapid-acting forms of insulin used to help lower mealtime blood sugar (glucose) levels in patients with diabetes. Continue reading

What is the difference between Soliqua and Xultophy?

Both Soliqua and Xultophy combine a long-acting insulin with a GLP-1 agonist: Xultopy brings together Tresiba (insulin degludec) and Victoza (liraglutide), while Soliqua combines Lantus (insulin glargine) with Adlyxin (lixisenatide). When used with diet and exercise for the treatment of type 2 diabetes, these agents can help you control blood sugar, insulin levels, and digestion and may help you lose weight. Continue reading

See also:

Related medical questions

Drug information

Related support groups